Drugs for coronavirus COVID-19

Main article: Coronavirus COVID-19

Approved products

Atheriksen

Main article: Atherixen (COVID-19 coronavirus drug)

Olumiant

Main article: Olumiant (COVID-19 coronavirus cure)]

Avifavir

Main article: Avifavir (COVID-19 drug)

Areplivir

Main article: Areplivir (drug against coronavirus COVID-19)

Hydroxychloroquine

Main article: Hydroxychloroquine

Ilsira (Biocad Levilimab)

Main article: Ilsira (Biocad Levilimab)

Mirobivir

Main article: Mirobivir (drug for coronavirus COVID-19)

COVID GLOBULIN

On April 1, 2021, Rostec announced that the Russian Ministry of Health approved the use of a specific immunoglobulin intended for the treatment of coronavirus infection, COVID-globulin. Read more here.

Coronavir

Main article: Coronavir (a drug for the treatment of COVID-19)

Skyvira

The list of drugs for the treatment of COVID-19 also includes the drug Skivira manufactured by Promomed Group of Companies, which announced this on August 24, 2022. Read more here.

Surfactant-BL

Russian the drug developed Surfactant-BL for the treatment of severe lung lesions, frequent with, COVID-19 is included in the latest version of the Temporary Guidelines "Prevention, Diagnosis and Treatment of Coronavirus Infection (COVID-19)." Ministry of Health of Russia This was Biosurf announced on March 2, 2021. More. here

Evusheld

Main article: Evusheld (COVID-19 coronavirus cure)

 Are antibiotics an effective means of preventing and treating coronavirus infection?

No, antibiotics against viruses do not work. They only allow you to treat bacterial infections.

 CoronavirusCOVID-19 is a virus, and therefore antibiotics should not be used to prevent and treat coronavirus infection.

2024: 17,000 coronavirus patients died in EU and US due to antimalarial treatment

In early January 2024, it became known that approximately 17 thousand patients with COVID-19 died in the European Union and the United States due to the use of the antimalarial drug hydroxychloroquine. This tool was prescribed during the first wave of coronavirus.

During World War II, hydroxychloroquine was used for mass prevention of malaria. Soldiers who took it became less likely to develop rashes and arthritis. Although the drug is considered generally safe, its use can cause a number of side effects.

A report examining the effects of hydroxychloroquine on patients with COVID-19 has been published in the journal Biomedicine & Pharmacotherapy. The data are based on an analysis of 44 research papers covering almost 100 thousand patients aged 56-75 years from Belgium, Spain, Italy, Turkey, France and the USA. It says that hydroxychloroquine was prescribed "despite the lack of evidence to support its clinical benefit." The researchers concluded that in countries for which data are available, the number of excess deaths associated with the use of hydroxychloroquine was 16,690 for the period from December 1, 2019 to March 15, 2021. In fact, this number can be significantly higher.

The World Health Organization (WHO) officially does not recommend the use of hydroxychloroquine as a means of preventing COVID-19. This recommendation is based on the results of six trials involving more than 6,000 people who were not infected with COVID-19 and took hydroxychloroquine. The use of the drug, as it turned out, has a slight or zero effect on the indicators of prevention, hospitalization or mortality in connection with coronavirus. However, the risk of symptoms of diarrhea, nausea, abdominal pain, drowsiness and headache may increase.^[1]

2022

Drug sales in Russia exceeded ₽500 billion

In Russia, for more than two years of the coronavirus pandemic, 500 billion rubles were spent on drugs for COVID-19. RBC writes about this in November 2022 with reference to data from the Headway Company, which monitors tender purchases in the pharmaceutical industry.

According to the company, from January 2020 to the end of September 2022, state customers sent 324.5 billion for medicines, the rubles remaining amount was spent themselves. Russians

Sales of drugs from coronavirus in Russia for 2 years exceeded ₽500 billion

It is also noted that in terms of procurement volumes in the state segment, the most popular drugs were Favipiravir, Rivaroxaban, Levilimab and Olokizumab.

Ilya Yasny, head of the scientific expertise of the Inbio Ventures Foundation, noted that the latest version of the protocols for treating coronavirus infection still contains drugs with low efficacy or generally ineffective. Among them, he named "Favipiravir" and "Arbidol." The general director of the marketing agency DSM Group, Sergei Shulyak, pointed out that the Russian recommendations were formed based on the experience of using drugs in practice, and not international protocols.

The publication notes that, despite the requests of the Ministry of Health to doctors not to prescribe antibiotics in the prehospital period without confirmed bacterial pneumonia, many still did it. Patients also self-purchased and took anticoagulants and antibacterial agents, which were read about online and in the media. This is confirmed by data on retail sales of drugs.

Although the Ministry of Health has repeatedly asked doctors not to prescribe antibiotics in the prehospital period, when bacterial pneumonia has not been confirmed, they did it anyway, and many patients took antibacterial agents and anticoagulants on their own, having read statements about their effectiveness in the media and the Internet. This is confirmed by data on retail sales of drugs included in Russian treatment regimens for COVID-19, adds RBC.^[2]

WHO reported new side effects of drugs against coronavirus

In September 2022, the World Health Organization (WHO) WHO warned of new side effects of drugs against the coronavirus COVID-19. We are talking about drugs with substances such as molnupiravir and nirmatrelvir/ritonavir. WHO cites data from Japanese and Australian regulators.

Japan's Ministry of Health, Labor and Social Services (MHLW), Japan's Medicines and Medical Devices Agency (PMDA) have reported risks of anaphylaxis with two antiviral drugs at home and abroad. The causality between anaphylaxis and molnupiravir was considered reasonably possible in two of the eight cases in Japan, in one of the 11 cases reported abroad.

Regulators in Japan and Australia are proposing to update safety information prescribed for the treatment of a new coronavirus infection.

The regulator also reports two deaths, but the causality of the event cannot be established. The association of anaphylaxis with nirmatrelvir/ritonavir was considered reasonably possible in all four cases.

The Health Products Control Australia Authority (TGA) has announced an update to the information listed in the instructions of the two antivirals. Added risk of hypersensitivity with molnupiravir and nirmatrelvir/ritonavir. Medications are contraindicated in patients with a history of clinically significant hypersensitivity reactions to active ingredients or any other component within the drug, the WHO reported citing the TGA.

WHO included molnupiravir in the recommendations for the treatment of coronavirus in March 2022. Due to the lack of data, molnupiravir should be prescribed only to patients with a non-severe form of COVID-19, which are classified as the highest risk of hospitalization, the organization said. The recommendation was developed based on new data from six randomized controlled trials involving 4,796 patients.^[3]

Binnopharm Group has begun supplying the drug for coronavirus Favipiravir

On February 2, 2022, the pharmaceutical company Binnopharm Group (BFG) announced that it had delivered the first batch of Favipiravir to the Russian market, which was recommended by the Ministry of Health in protocols for the treatment of COVID-19. Marketing authorization for the drug was received in September 2021. Read more here.

Aveksima organizes the production of the antiviral drug Nobazit in the Yesipovo IP near Moscow

On January 18, 2022, the Moscow Region Development Corporation announced that the pharmaceutical company Aveksima is organizing the production of the antiviral drug Nobazit to combat COVID-19 as part of an investment project in the Yesipovo enterprise near Moscow. Read more here.

2021

Almost half a million patients diagnosed with COVID-19 were treated with levilimab

Almost half a million patients diagnosed with COVID-19 were cured thanks to the Russian drug - Biocad Levilimab. Biocad announced this on April 19, 2022. Read more here.

Russians spent 64 billion rubles on drugs for COVID-19

Russians spent more than 64 billion rubles in 2021 on medicines to treat the coronavirus COVID-19. This is evidenced by the data of the Center for the Development of Advanced Technologies (CRPT), the operator of the Honest Sign marking system. The top 5 corresponding drugs in terms of sales included:

• umifenovir - 16.8 billion rubles. The most famous trade name is "Arbidol." The efficacy and safety of umifenovir has not been proven in studies conducted according to international quality standards;
• immunomodulator interferon alpha-2B - 7.2 billion rubles. In other countries, this drug is rarely used to treat coronavirus infection;
• agent for the treatment of COVID-19 favipiravir - 2.9 billion rubles;
• antibiotic dexamethasone - 1 billion rubles;
• methylprednisolone - 800 million rubles.

Russians spent 64 billion rubles on drugs for coronavirus in 2021

In total, 144 million packages of drugs recommended for the treatment of coronavirus infection were sold in Russia at the end of 2021. Comparison with 2020 is not given.

Most of the money for the purchase of drugs in pharmacies was spent To Moscow in (5 billion rubles), (Moscow area 5 billion rubles) and the Krasnodar Territory (3 billion rubles).

The CRPT noted that labeling gives complete and accurate statistics on drugs, and also allows you to predict the availability of drugs and avoid their shortage.

From January 1, 2022, new temporary guidelines for the prevention, diagnosis and treatment of coronavirus infection developed by the Ministry of Health of the Russian Federation are in effect. The new version included data on the omicron strain. For the treatment of COVID-19 in inpatient conditions, a new Russian drug "MIR 19" is also recommended for the first time. The Ministry of Health excluded Arbidol from the new recommendations for the treatment of COVID-19 in patients at risk with a mild course of the disease.^[4]

New drug for coronavirus "Mir 19" registered in Russia

On December 22, 2021, the Ministry of Health of the Russian Federation registered a drug for the coronavirus COVID-19 called "World 19." It was developed by the FSBI "SSC Institute of Immunology" FMBA of Russia. Read more here.

The beginning of deliveries to Russian hospitals of biologics Betucladin created from berries and bark

At the end of November 2021, it became known about the beginning of deliveries to Russian hospitals of a biological product Betucladin created from a berry and birch bark for treatment. COVID-19 This is the development of Yakut scientists. Institute of Biological Problems of Cryolithozone of the Siberian Branch of the Russian Academy of Sciences More. here

The Ministry of Health of the Russian Federation recommends 3 drugs to stop cough in COVID-19

At the end of November 2021, the Ministry of Health of the Russian Federation updated temporary methodological recommendations for the prevention, diagnosis and treatment of the coronavirus COVID-19. In addition to recommendations for doctors on oxygen consumption and oxygenotherapy, drugs were indicated to treat cough in this infection.

In order to stop coughing in COVID-19, the Ministry of Health recommends using Rengalin, Butamirat and Levodropropropizin.

The Ministry of Health of the Russian Federation recommends 3 drugs to stop cough in COVID-19

The company "Materia Medica Holding," which produces "Rengalin," received permission from the Ministry of Health to conduct new clinical trials of two drugs.

By the end of 2021, a clinical study of the drug Prospekt is underway. It is intended for the therapy of asthenia. After suffering a coronavirus infection, many people feel weak and quickly tire. A new drug could help get rid of these consequences.

According to the World Health Organization (WHO), dry cough is also the second most common symptom of COVID-19, which 68% of patients complain about. Dry cough is characterized by the absence of sputum, and in patients with coronavirus it is very deep. However, the presence of a dry cough does not mean that it is a covid cough, as it can be similar with an allergic reaction, dry air indoors, as well as due to smoking, asthma or gastroesophageal reflux (GERD).

According to the Ministry of Health, one or more signs may indicate infection with a coronavirus infection, in addition to temperatures above 37,5S: cough, dry or with poor sputum, shortness of breath, chest congestion, SpO2 ≤ 95%, sore throat, nasal congestion or moderate rhinorrhea, impaired or lost sense of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle aches, headache, vomiting, diarrhea, skin rash).^[5]

The head of the Ministry of Health of the Russian Federation stated the side effects of drugs from coronavirus

On October 8, 2021, the head of the Ministry of Health of the Russian Federation, Mikhail Murashko, warned of side effects from drugs intended for the treatment of coronavirus (COVID-19) infection.

Doctors note, among other things, toxic liver lesions after the treatment of a new coronavirus infection. Apply... antiviral drugs, which simply need to be used for life saving, but all of them are drugs that, among other things, have side effects, the minister said.

Health Minister Mikhail Murashko warned of side effects from drugs intended for the treatment of coronavirus (COVID-19) infection

Nevertheless, doctors are forced to use anti-coronavirus drugs, since the incidence and mortality from COVID-19 continues to grow in Russia by October 8, 2021. According to Murashko, more than 1 million patients with coronavirus are under the supervision of doctors. On October 8, a record number of deaths from coronavirus in 24 hours was registered in the Russian Federation - 926 people died.

Earlier, pharmacologists analyzed data on the safety of favipiravir and its products used to treat the coronavirus COVID-19. It turned out that the instructions for the Japanese drug "Avigan" say about the likelihood of motor disorders in patients: night walking syndromes and fast running, as well as an increased risk of falls. Experts believe this may be due to the effects of the drug on the central nervous system.

A document with a detailed analysis of the data known today on the side effects of the drug was published by the Information Center for Pharmacotherapy in Patients with the New Coronavirus Infection COVID-19 "PharmaCOVID" on the basis of the FSBEI DPO RMANPO Ministry of Health of Russia.

Reports that the drug has side effects are usually associated with cases when the doses of the drug are "exceeded," Sergei Babak, professor at the Department of Phthisiology and Pulmonology of the Faculty of Medicine of the Moscow State Medical University, told RBC.^[6]

Moscow allocated 696.3 million rubles for the procurement of donor plasma for the treatment of COVID-19

Moscow has allocated about 696.3 million rubles for the procurement of donor plasma for the treatment of coronavirus (COVID-19) infection. This was announced on September 28, 2021 by the press service of the mayor and the government of the capital following a meeting of the presidium of the city government.

According to the decree signed by Moscow Mayor Sergei Sobyanin, 510.8 million rubles will be spent on the procurement, processing, storage and security of donated blood and its components, and 97.3 million rubles will be spent on plasma processing for the production of the blood drug "COVID-globulin human immunoglobulin against COVID-19." Also, 88.2 million rubles are planned to spend payments to donors for the delivery of plasma with antibodies to coronavirus.

Moscow allocated 700 million rubles for the procurement of donor plasma for the treatment of coronavirus

According to the authorities of the capital, donor plasma with antibodies is used to treat patients in metropolitan hospitals. The method has proven to be effective and is included in clinical guidelines as one of the elements of complex therapy. Studies conducted in Moscow confirm that plasma can be used for transfusion to patients with coronavirus infection and the production of immunoglobulin both from donors who have recovered from COVID-19 and from persons who have undergone a full course of vaccination with the Sputnik V combined vector vaccine or revaccination with a single-component Sputnik Light or Sputnik V.

In September 2021, on the basis of the branch of the Clinical Hospital No. 1 named after N.I. Pirogov in Moscow, a point for the preparation of plasma with antibodies to COVID-19 was opened in test mode. Donor reception and plasma procurement is carried out by an on-site team of specialists from the O.K. Gavrilov Blood Center.

It is assumed that the funds and the opening of a specialized donor point will increase the volume of plasma procurement in Moscow by more than 2.5 times, to 8.2 tons per month. By the end of 2021, it is planned to prepare up to 21.9 tons of donated blood.^[7]

Use of drugs from the group of monoclonal virus neutralizing antibodies for the treatment of COVID-19

In mid-September 2021, it became known about a new therapy that began to be used against those infected with the COVID-19 coronavirus in Moscow. We are talking about the use of drugs from the group of monoclonal virus neutralizing antibodies.

Pregnant women with coronavirus infection became patients who were primarily recommended new therapy. In Moscow, new algorithms for the provision of medical care have been developed for them.

It is noted that when using the drugs, doctors did not detect adverse events, the virus was quickly neutralized, and the condition of the patients improved. According to the new technology, patients are treated in special hospitals on the basis of the city clinical hospital No. 15 named after O.M. Filatov and the city clinical hospital No. 52. By September 16, 2021, more than 70 patients received new therapy.

In the Russian Federation, the use of drugs from the group of monoclonal virus neutralizing antibodies for the treatment of COVID-19 began

According to Anastasia Rakova, Deputy Mayor of Moscow for Social Development, according to the conclusion of the medical commission for the treatment of women with COVID-19 during pregnancy, it is possible to use drugs from the group of monoclonal virus neutralizing antibodies. No adverse events were reported with the drugs, but rapid neutralization of the virus and improvement in the condition of the patients were noted. During pregnancy, women are more susceptible to respiratory viral infections due to physiological changes in the body. At the same time, they are at risk for the severe course of SARS and COVID-19.

Earlier, Moscow approved an algorithm for providing medical care to pregnant women with COVID-19. According to the deputy mayor of the capital on the issue of social development Anastasia Rakova, the leading specialists of the city took part in its development. She noted that for expectant mothers, the identification of a new coronavirus infection is already a lot of stress.

According to Rakova, such therapy is successfully used in, USA,, and France Germany Italy other countries.^[8]

2020

Sales of drugs recommended from COVID-19 exceeded 120 billion rubles

Sales of drugs recommended by the Ministry of Health of the Russian Federation for the treatment of coronavirus (COVID-19) infection in 2020 reached 120.8 billion rubles against 53.1 billion rubles a year earlier. This is evidenced by the data of the analytical company AlphaRM.

Most of this market in 2020 fell on the purchase of drugs in pharmacy chains - 61.7 billion rubles. Through public procurement, products worth 59.1 billion rubles were delivered to medical institutions, which is three times more than the result of 2019. In units, the volume of the market under consideration more than doubled (reached 156.3 million packages) both in the public sector (37.1 million packages) and in the pharmacy (119.2 million).

It is noted that most of the drugs, after their inclusion in the treatment protocols, improved their positions and began to be more actively implemented both in the pharmacy segment and in the state segment. About 25 international non-proprietary names (INNs) in 2020 showed positive market growth relative to the previous year. Four drugs first entered the market. As for the INN excluded from the recommendations, the demand for them can be traced by the dynamics over two years.

Analysts also calculated which drugs increased their sales the most during the pandemic. The leader was the anticoagulant rivaroxaban (trade name Xarelto) from. Bayer Its increase amounted to more than 77%, the total amount of sales - 20.7 billion rubles. This is followed by the antiviral agent umifenovir, represented by four different trade names. His sales increased by 407%, and revenue exceeded 15 billion rubles. The third in the AlphaRM rating was another tool for folding - blood apixaban with an increase in sales by incomplete 123% and 11 billion rubles in sales for the year.^[9]

Doctors in Russia sell treatment schemes for coronavirus on social networks

At the end of November 2020, it became known about an internal audit initiated by the Ministry of Health of the Tver Region after information appeared about the sale by the therapist of the city hospital No. 6 of instructions for the treatment of the coronavirus COVID-19. Read more here.

Directors of the pharmacy chain "Pharmacy" fired for refusing to purchase drugs from coronavirus

On October 27, 2020, Deputy Prime Minister of the Khabarovsk Territory Yevgeny Nikonov dismissed Denis Ulybyshev, director of the regional budget chain of pharmacies Pharmacy, for refusing to purchase medicines for pneumonia caused by the COVID-19 coronavirus. Nikonov announced this decision at a meeting of the regional headquarters on coronavirus. Read more here.

100 rubles per tablet. FAS set a limit on the price of drugs for coronavirus

On October 16, 2020, the Federal Antimonopoly Service (FAS) set a maximum selling price for drugs for the treatment of COVID-19 coronavirus based on favipiravir. It will be 100 rubles per tablet or 5500 rubles per package, the press service of the department said.

The maximum cost of the drug, taking into account premiums, can be 6875 rubles with VAT. By October 16, 2020, the price of the drug in Moscow pharmacies varies from 11,320 rubles to 16,306 rubles. Thus, its cost will be more than halved, the FAS noted.

As of October 16, 2020, in Russia, drugs for coronavirus with the international non-proprietary name Favipiravir are produced by R-Pharm - Coronavir and Promomed - Areplivir.

Limiting the maximum selling price for the drug from Coronavirus "Areplivir" will increase its availability for the population of Russia, the chief executive director of the manufacturer of such drugs "Promomed" Andrei Babies believes.

I can say for sure that our maximum selling price is 4 thousand per package without VAT. Or 4400 including VAT. And then there is the standard restriction of the retail mark-up. We now cannot name the final cost, as it will depend on the cost of distribution and markup of retail chains, "RIA Novosti told Mladentsev.

The decision on the maximum price for the drug of 100 rubles per tablet was made after analyzing prices in countries where favipiravir is in circulation. In India and China, in particular, the original Avigan drug is sold at a price of 100 rubles per tablet.

This price was discussed as indicative for use in Russia and was supported by all members of the commission, - explained the deputy head of the FAS Timofey Nizhegorodtsev.[10]

The results of the final clinical studies of "Coronavira" have been published in Russia

On 15 Oct 2020, R-Pharm reported the final results of the clinical trial of Coronavir. Read more here.

Russian drug Ilsira in the list of vital and essential drugs

In accordance with the order of the Government of the Russian Federation of October 12, 2020 No. 2626-r, levilimab, a drug manufactured by the biotechnological company Biocad, is included in the list of vital and essential drugs. Biocad announced this on October 15, 2020. Read more here.

Scientists have proposed a method for suppressing secondary inflammation in COVID-19

On September 29, 2020, it became known that scientists from NUST MISIS together with colleagues from the Federal Research Center "Crystallography and Photonics" of the Russian Academy of Sciences and the First Moscow State Medical University named after I.M. Sechenov proposed a method for diagnosing and treating patients with coronavirus, which will help prevent the development of secondary tissue inflammation, extremely dangerous for patients with COVID-19. The article is published in the journal Frontiers in Immunology. The details are here.

In Russia, found a way to treat COVID-19 without mechanical ventilation

On September 10, 2020, it became known about the creation in Russia of a method of treating patients infected with the COVID-19 coronavirus without the use of artificial lung ventilation (IVL). We are talking about the use of inhalation with a helium-oxygen mixture, Valery Chereshnev, president of the Russian Scientific Society of Immunologists, scientific director of the Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences, told reporters.

According to him, the treatment of 50 patients with COVID-19 in this way only in one case required an additional connection to ventilators. A new method of combating coronavirus infection was tested in a republican hospital in Komi. The experience of imprisonment in a republican hospital in Syktyvkar gave a positive result, he said.

In the Russian Federation found a way to treat coronavirus without mechanical ventilation

The scientist stressed that artificial ventilation of the lungs is a rather heavy burden on the body. The helium-oxygen mixture, which is heated to 90-95 degrees, with pneumonia developing against the background of coronavirus infection, significantly exceeds mechanical ventilation. At high temperatures, the coronavirus dies.

Earlier, during his report "The COVID-19 epidemic: problems, solutions, prospects," Chereshnev said that inhalation with helium-oxygen mixtures heated to high temperature (Group of company Systematica) will help reduce the severity of the course of coronavirus infection. By September 2020, the Ural Branch of the Russian Academy of Sciences and an enterprise in St. Petersburg are working on research in this area.

Chereshnev said that the devices that were originally used for such inhalations had to be improved. Microbiologists have found that both living and dead viruses are in the exhaled air, thus resulting in a "self-ignition mechanism." Then scientists decided to make a device with separate systems of inhaled and exhaled air.^[11]

The Russian drug "Ilsira" is included in the methodological recommendations of the Ministry of Health of the Russian Federation

On September 3, 2020 Ministry of Health of the Russian Federation COVID-19 , a domestic original drug with the trade name "" (INN Ilsira- levilimab) was included in the guidelines for therapy. The drug is developed in a biotechnology company BIOCAD and is used to prevent a cytokine storm, one of the worst complications in coronavirus infection. Biocad announced this on September 4, 2020. More. here

Blood plasma of 4,000 people is used to produce a cure for COVID-19 in South Korea

More than 4,000 South Koreans who have recovered from COVID-19 have expressed a desire to donate their blood plasma. This became known on August 7, 2020. The Korean Centers for Disease Control and Prevention said 500 people have passed since July 13, 2020, and it will be used to produce drugs for coronavirus after clinical trials.

It was difficult for us to accelerate the development of a cure for COVID-19 in a situation where only 200 recovered patients expressed a desire to donate blood. A massive donation from recovered patients at Shinchonji Church will address the lack of blood for research, said a spokesman for Green Cross Pharma, a biopharmaceutical company in South Korea.

During the first quarter of 2020, the rapid spread of the virus hit church members in Daegu, South Korea. The first signs of the crisis appeared with disputes about mass visitors from China before the infection of believers in the church.

There is no evidence that Sinchonji provided incomplete or altered lists. There were only minor differences.

11 non-governmental organizations, including the European Coordination of Associations for Freedom of Conscience, presented a document for the "annual report of the UN High Commissioner for Human Rights" to the UN Secretary General at the 44th session of the UN Human Rights Council. The report is entitled "Members of Sinchonji as scapegoats in the situation with COVID-19 in South Korea."

The virus cannot serve as an excuse for the violation of human rights and religious freedom of hundreds of thousands of believers. Intolerance, violence and discrimination against Sinchonji must be stopped.

Just as Jesus sacrificed his blood for life, we hope that the blood of believers can have a positive impact on overcoming the current situation, "said Lee Man Hee.

{{quote 'We had a discussion with the health authorities to draw up a detailed donation plan. Some of the recovered members have already donated blood plasma individually, feeling grateful for the help from the government and medical staff. They expressed a desire to contribute to society, - said the representative of the church. }}

As of August 3, 2020, South Korea reported 14,389 confirmed cases of infection and 301 deaths from coronavirus.

Launch of the platform for the development of drugs for COVID-19

At the end of July 2020, the ChemRar Research Institute (NII) announced the launch of a platform for the development of new drugs for the coronavirus COVID-19. Read more here.

R-Pharm has registered the drug Coronavir for the treatment of coronavirus infection

On July 8, 2020, the R-Pharm Group announced the completion of the registration process for the treatment of coronavirus infection COVID-19 of the lung and moderate course - Coronavir (INN: favipiravir). The production of the drug, organized with the participation of the Industrial Development Fund, will be carried out at the R-Pharm enterprise in the city of Yaroslavl. Read more here.

Russian drugs for the treatment of coronavirus began to be supplied abroad

On July 2, 2020, it became known about the start of deliveries of Avifavir abroad. The export of the drug for the treatment of coronavirus infection (COVID-19) became possible due to the increase in production. Read more here.

Ministry of Health approved the Russian drug for coronavirus "Areplivir"

On June 25, 2020, the Ministry of Health of the Russian Federation announced the approval of the drug "Areplivir," intended to combat the coronavirus COVID-19. The medicine will be produced at the Biochemist enterprise in Saransk. Read more here.

In Russia, created a drug for the treatment of mild forms of coronavirus

On June 19, 2020, R-Pharm announced the imminent release of the drug for the treatment of mild and moderate forms of coronavirus COVID-19. The novelty was called "Coronavir." Read more here.

"Synthesis" launched the production of a drug for the treatment of COVID-19 in Kurgan

On June 16, 2020, the company Kurgan Joint-Stock Company of Medical Products and Products Sintez (included in, the AFK Sistema shareholder is also "") Natsimbio Rostec State Corporation announced the expansion of the production capacity of the drug "," Hydroxychloroquine recommended Ministry of Health of Russia in the treatment protocols. coronavirus infections

As of June 2020, Hydroxychloroquine can be produced both at the site of CJSC Biokom (a subsidiary of Sintez, owns a registration certificate for the drug) in Stavropol, and at the plant of Sintez itself in Kurgan. Read more here.

In Russia, registered the second drug for the treatment of coronavirus - "Levilimab"

On June 6, 2020, the Ministry of Health of Russia announced the registration of the second drug for the treatment of coronavirus COVID-19. The medicine is called "Levilimab" (trade name "Ilsira"). It is produced by the biotech company Biocad. Read more here.

The Ministry of Health of the Russian Federation has registered the first cure for coronavirus - Avifavir

On May 30, 2020, the Ministry of Health of the Russian Federation registered the first medicine in Russia for the treatment of coronavirus COVID-19. The drug was called Avifavir. Read more here.

Russian drug against COVID-19 called Avifavir

On May 22, 2020, the Russian Direct Investment Fund (RDIF) and the ChemRar group of companies announced the name of the drug, which, according to partners, is capable of treating patients with the COVID-19 coronavirus . The medicine will be sold under the name "Avifavir." Read more here.

11 clinical research centers joined the trial of the Russian drug Levilimab

As of May 12, 2020, the Ministry of Health of the Russian Federation approved clinical trials of the Russian drug with INN-levilimab in 11 medical centers. Doctors note the positive dynamics of patients with confirmed moderate to severe coronavirus. Registration of the drug in the Ministry of Health of the Russian Federation is expected at the end of May 2020. This was reported on May 12, 2020 in BIOCAD. To confirm the effectiveness of the drug, it is with coronavirus infection that the company begins organizing phase 3 clinical trials. Read more here.

Levilimab will be tested for COVID-19 therapy

On April 27, 2020, it became known that Levilimab at the end of May it could receive registration under a special procedure approved by Decree Governments of the Russian Federation of 03.04.2020 No. 441, and will be tested for therapy from. COVID-19 The company Biocad received permission to conduct a clinical study of the efficacy and safety of levilimab in patients with severe coronavirus infection. Ministry of Health

As reported, according to the Interim Methodological Recommendations for the Prevention, Diagnosis and Treatment of COVID-19, prepared by the Ministry of Health of the Russian Federation, studies conducted in the world prove that mortality in COVID-19 is associated, among other things, with an increase in interleukin-6 levels. The findings prompted the initiation of studies of the effectiveness of interleukin-6 signaling pathway inhibitors in the treatment of severe and critical pneumonia in COVID-19. A month ago, the US government issued a grant for a clinical trial of the American inhibitor tocilizumab (originally registered for use in rheumatoid arthritis in the United States) in patients with COVID-19. Levilimab can become a similar domestic remedy for coronavirus. Read more here.

Existing drugs used to treat COVID-19

The darknet began to sell the blood of those who recovered from coronavirus

In early April 2020, cyber threat researchers at McAfee discovered a post on a web forum on the dark web, the author of which offered blood for sale from a person who recovered from Covid-19 infection.

The announcement is likely related to the latest news, according to which some patients showed improvement after transfusion of plasma from recovered patients. According to the British edition of the Guardian, improvement was observed in two patients in two different pilot studies, one in Wuhan and the other in Shenzhen. However, a randomized trial has not yet been conducted, and an independent attempt to transfuse blood of unknown origin, especially if it was obtained on the black market, can be deadly.

Cyber ​ ​ threat researchers at McAfee found a post on a web forum on the dark web, the author of which offered blood for sale from a person who recovered from Covid-19 infection

McAfee lead researcher Christian Beek and principal investigator Raj Samani note that the explosion of fraud amid global events was not a surprise to cybersecurity experts, but the coronavirus pandemic has identified many unexpected threat vectors.

We've seen numerous examples of fraudsters abusing people's trust using current news, and current global events are no exception, "Bik and Samani wrote on their blog. - Covid-19 as a bait does not lose its relevance. We regularly identify all new campaigns that use the coronavirus in selfish interests.

Bik and Samani study the underground markets of Onion and other services using channels in the Telegram messaging service. Among other things, they found an incredible number of sellers cashing in on face masks. One site sold masks at a price 10 times the retail price. The seller was allegedly a legal wholesaler and supplier of medical masks, but did not disclose his identity.^[12]

Ivermectin completely suppresses COVID-19 in the body in 48 hours

On April 9, 2020, it became known about a drug that can completely suppress coronavirus COVID-19 the body in 48 hours. We are talking about the anti-parasitic drug ivermectin. More. here

RNC named after A.M. Granova announced the production of a drug for the treatment of the main complication of coronavirus

On March 27, 2020, it became known that a drug is being produced in St. Petersburg for the therapy of the main complication of coronavirus.

We are talking about a drug of pulmonary surfactant developed at the Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. Granova (director of the institute, doctor of medical sciences - Dmitry Maistrenko) in St. Petersburg, which has been tested in clinical trials and approved since 2008. for the treatment of non-cardiogenic pulmonary edema, from which, as of March 2020, patients with coronavirus mainly die. Surfactant is a complex lipid-protein complex located on the surface of the alveoli. It provides breath by reducing surface tension and prevents alveoli walls from sticking together when exhaled. Surfactant is synthesized by specialized cells - type II alveolocytes and is released on the surface of the alveolar epithelium. Read more here.

RDIF will invest hundreds of millions of rubles in the production of an analogue of the drug for the treatment of coronavirus

On March 26, 2020, the Russian Direct Investment Fund (RDIF) announced the creation of a joint venture with the ChemRar group of companies that will create an analogue of Favipiravir ( developed by Fujifilm). The latter in China is called an effective treatment for coronavirus. Read more here.

An inhaler has been created in Russia to facilitate the treatment of coronavirus

On March 24, 2020, it became known about the company's development Personal Medication & Health Management (PM&HM) of an inhaler that facilitates treatment. coronavirus COVID-19 The cost of the device will be from 3 thousand. rubles More. here

Trump: a cure for malaria will help to recover from coronavirus

On March 19, 2020, US President Donald Trump announced that the malaria drug , hydroxychloroquine, can be used to treat a new type of coronavirus.

The best part is that it has existed for a long time, so we know that if everything goes wrong as planned, he will not kill anyone , "he said.

Trump spoke about testing a cure for coronavirus

According to him, the drug, which is used to treat malaria and arthritis, showed "very encouraging results" in the treatment of the coronavirus COVID-19.

We intend to immediately make the drug available, - promised the head of the White House, noting that drug trials are ongoing.

Trump also said that Gilead's drug, Remdesivir, intended for other purposes, has shown very good results in the fight against coronavirus. This medicine will soon have to be approved by the Food and Drug Administration (FDA), the American leader said.

Donald Trump has repeatedly stated that the country will quickly cope with the COVID-19 epidemic. To support American citizens, the government decided to allocate a thousand dollars from the budget to them.

During a briefing at the White House, the president said that he had instructed the FDA to remove all bureaucratic barriers in order to speed up the process of clinical trials of old drugs for use against coronavirus.^[13]

In turn, FDA leader Stephen Hahn said at a press conference that the department will allow these drugs to be used under the compassionate use program, when doctors ask the FDA for permission to use experimental drugs (old drugs in this case are experimental) for their prescription to patients. According to him, he does not want to give false hopes, but still hopes for favorable results.

Fujifilm helps coronavirus patients recover

On March 18, 2020, it became known about the effectiveness of Avigan (Favipiravir) in the treatment of SARS-CoV-2 coronavirus. The drug is produced by a subsidiary of the Japanese manufacturer Fujifilm - Toyama Chemical. Read more here.

IBM and US authorities begin to use supercomputers to find drugs for coronavirus

In March 2020, IBM announced the creation of the COVID-19 High Performance Computing Consortium, which plans to use the power of supercomputers to combat a new type of coronavirus. The consortium was formed in collaboration with the US Department of Science and Technology Policy (White House office of science and technology policy), the US Department of Energy and a number of research and educational institutions. Read more here.

Notes